top of page

Introducing
OsciFlex

Developing technologies for venous disease based on molecular insights

OsciPulse figure 2.jpg
Abstract Lines

Venous thromboembolism (VTE) is a leading cause of complication and death for hospitalized patients. Patients who sustain a VTE have approximately twice the length of stay and total inpatient cost as patients who do not.

​

Prevention of hospital associated VTE (HA-VTE) is a national priority.

>70% of ALL hospital patients are considered at risk.

There are 300,000-600,000 cases per year in the US, most in hospitals.

Approximately 1 in 5 patients are readmitted within 30 days.

This is the LEADING cause of preventable hospital deaths in the US (~100,000/year).

These clots cost the Healthcare System $7-$10 Billion annually in the U.S.

FAQ
PHT logo.png
NSF SBIR logo_edited.png
CVI logo_edited.png
nhlbi-sbir-sttr-special-topics.png

Contact

OsciFlex LLC

2212 Walnut Street

Floor 1, Unit 3
Philadelphia, PA, 19103
Ph: (609) 977-7258

Be in the Know

Reach out to learn more about Osciflex and our latest developments. 

Thanks for submitting!

Follow us on

LinkedIn

​

© 2023 by Osciflex.

bottom of page